SrasV1, PubMed, Corpus, bibRecord, 000350

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.

Identifieur interne : 000350 ( PubMed/Corpus ); précédent : 000349; suivant : 000351

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.

Auteurs : Yu-Chen Cao ; Qi-Xin Deng ; Shi-Xue Dai

Source :

Travel medicine and infectious disease [ 1873-0442 ] ; 2020.

RBID : pubmed:32247927

Abstract

The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.

DOI: 10.1016/j.tmaid.2020.101647
PubMed: 32247927

Links to Exploration step

pubmed:32247927

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.</title>
<author><name sortKey="Cao, Yu Chen" sort="Cao, Yu Chen" uniqKey="Cao Y" first="Yu-Chen" last="Cao">Yu-Chen Cao</name>
<affiliation><nlm:affiliation>The Second Clinical School, Southern Medical University, Guangzhou, 510515, Guangdong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Deng, Qi Xin" sort="Deng, Qi Xin" uniqKey="Deng Q" first="Qi-Xin" last="Deng">Qi-Xin Deng</name>
<affiliation><nlm:affiliation>The Second Clinical School, Southern Medical University, Guangzhou, 510515, Guangdong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dai, Shi Xue" sort="Dai, Shi Xue" uniqKey="Dai S" first="Shi-Xue" last="Dai">Shi-Xue Dai</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, 510080, Guangdong, China. Electronic address: shixuedai@hotmail.com.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32247927</idno>
<idno type="pmid">32247927</idno>
<idno type="doi">10.1016/j.tmaid.2020.101647</idno>
<idno type="wicri:Area/PubMed/Corpus">000350</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000350</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.</title>
<author><name sortKey="Cao, Yu Chen" sort="Cao, Yu Chen" uniqKey="Cao Y" first="Yu-Chen" last="Cao">Yu-Chen Cao</name>
<affiliation><nlm:affiliation>The Second Clinical School, Southern Medical University, Guangzhou, 510515, Guangdong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Deng, Qi Xin" sort="Deng, Qi Xin" uniqKey="Deng Q" first="Qi-Xin" last="Deng">Qi-Xin Deng</name>
<affiliation><nlm:affiliation>The Second Clinical School, Southern Medical University, Guangzhou, 510515, Guangdong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dai, Shi Xue" sort="Dai, Shi Xue" uniqKey="Dai S" first="Shi-Xue" last="Dai">Shi-Xue Dai</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, 510080, Guangdong, China. Electronic address: shixuedai@hotmail.com.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Travel medicine and infectious disease</title>
<idno type="eISSN">1873-0442</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32247927</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0442</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Travel medicine and infectious disease</Title>
<ISOAbbreviation>Travel Med Infect Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.</ArticleTitle>
<Pagination><MedlinePgn>101647</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1477-8939(20)30116-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tmaid.2020.101647</ELocationID>
<Abstract><AbstractText>The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName>
<ForeName>Yu-Chen</ForeName>
<Initials>YC</Initials>
<AffiliationInfo><Affiliation>The Second Clinical School, Southern Medical University, Guangzhou, 510515, Guangdong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Deng</LastName>
<ForeName>Qi-Xin</ForeName>
<Initials>QX</Initials>
<AffiliationInfo><Affiliation>The Second Clinical School, Southern Medical University, Guangzhou, 510515, Guangdong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dai</LastName>
<ForeName>Shi-Xue</ForeName>
<Initials>SX</Initials>
<AffiliationInfo><Affiliation>Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, 510080, Guangdong, China. Electronic address: shixuedai@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Travel Med Infect Dis</MedlineTA>
<NlmUniqueID>101230758</NlmUniqueID>
<ISSNLinking>1477-8939</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Corona virus disease 2019</Keyword>
<Keyword MajorTopicYN="N">Phase III clinical trial</Keyword>
<Keyword MajorTopicYN="N">Remdesivir</Keyword>
<Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus 2</Keyword>
</KeywordList>
<CoiStatement>Declaration of competing interest The authors report no conflicts.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32247927</ArticleId>
<ArticleId IdType="pii">S1477-8939(20)30116-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.tmaid.2020.101647</ArticleId>
<ArticleId IdType="pmc">PMC7151266</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cytokine. 2018 Apr;104:8-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29414327</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2020 Mar 7;395(10226):764-766</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105609</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2020 Mar 19;382(12):1177-1179</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074444</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Feline Med Surg. 2019 Apr;21(4):271-281</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30755068</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chembiochem. 2020 Mar 2;21(5):730-738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2020 Apr;92(4):418-423</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31967327</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22446091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):457-460</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32009228</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000350 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000350 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32247927
   |texte=   Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:32247927" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki